RADIATION THERAPY FOR THE TREATMENT OF LOCALLY ADVANCED AND METASTATIC PROSTATE CANCER

Consensus statement, 1997, Guidelines for PSA following radiation therapy: American Society for Therapeutic Radiology and Oncology Consensus Panel, Int J Radiat Oncol Biol Phys, 37, 1035 Bagshaw, 1988, Status of radiation treatment of prostate cancer at Stanford University, NCI Monogr, 7, 47 Blitzer, 1985, Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis, Cancer, 55, 1468, 10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO;2-M Bolla, 1997, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin, N Engl J Med, 337, 295, 10.1056/NEJM199707313370502 Bolla M, Collette L, Gonzalez D, et al: Long-term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC Study, San Antonio, TX, 41st Annual ASTRO Meeting, 1999, pp 147 Carroll, 1997, Focal therapy for prostate cancer 1996: Maximizing outcome, Urology, 49, 84, 10.1016/S0090-4295(97)00174-X Corn, 1995, Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment, Int J Radiat Oncol Biol Phys, 32, 325, 10.1016/0360-3016(94)00618-U Crook, 1995, Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients, Urology, 45, 624, 10.1016/S0090-4295(99)80054-5 D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 del Regato, 1993, Twenty years follow-up of patients with inoperable cancer of the prostate (stage C) treated by radiotherapy: Report of a national cooperative study, Int J Radiat Oncol Biol Phys, 26, 197, 10.1016/0360-3016(93)90197-4 Denmeade, 1996, Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer, Prostate, 28, 251, 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G DeWeese, 1998, Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure, J Urol, 159, 591, 10.1016/S0022-5347(01)63990-9 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1036, 10.1056/NEJM199810083391504 Forman, 1996, Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: Results of a dose escalation study, Int J Radiat Oncol Biol Phys, 34, 655, 10.1016/0360-3016(95)02202-3 Fuks, 1991, The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125-I implantation, Int J Radiat Oncol Biol Phys, 21, 537, 10.1016/0360-3016(91)90668-T Furuya, 1995, Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction, Endocrinology, 136, 1898, 10.1210/en.136.5.1898 Furuya, 1996, Expression of bcl-2 and the progression of human and rodent prostatic cancers, Clin Cancer Res, 2, 389 Gleave, 1996, Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer, J Urol, 155, 213, 10.1016/S0022-5347(01)66598-4 Granfors, 1998, Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study, J Urol, 159, 2030, 10.1016/S0022-5347(01)63235-X Hall, 1994 Hanks, 1996, Conformal technique dose escallation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen greater than or equal to 10 ng/mL, Int J Radiat Oncol Biol Phys, 35, 861, 10.1016/0360-3016(96)00207-6 Hanks, 1997, Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study, Int J Radiat Oncol Biol Phys, 37, 543, 10.1016/S0360-3016(96)00602-5 Hanks, 2000, RTOG Protocol 92-02: A Phase III Trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate, ASCO 2000, 327a Hanlon, 2000, Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external beam radiation, Urology, 55, 725, 10.1016/S0090-4295(99)00605-6 Holzman, 1991, The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer, J Urol, 146, 1578, 10.1016/S0022-5347(17)38171-5 Huggins, 1941, The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Res, 1, 293 Krasilnikov, 1999, Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells, Mol Carcinog, 24, 64, 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2 Kuban, 1995, Potential benefit of improved local tumor control in patients with prostate carcinoma, Cancer, 75, 2373, 10.1002/1097-0142(19950501)75:9<2373::AID-CNCR2820750930>3.0.CO;2-2 Kyprianou, 1997, bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells, Int J Cancer, 70, 341, 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I Laramore, 1993, Fast neutron radiotherapy for locally advanced prostate cancer: Final report of Radiation Therapy Oncology Group randomized clinical trial, Am J Clin Oncol, 16, 164, 10.1097/00000421-199304000-00018 Laverdiere, 1997, Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer, Int J Radiat Oncol Biol Phys, 37, 247, 10.1016/S0360-3016(96)00513-5 Lawton, 1999, Updated results of the phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate, ASCO 1999, 311a Lawton, 2001, Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 49, 937, 10.1016/S0360-3016(00)01516-9 Leith, 1994, In vitro radiation sensitivity of the LNCaP prostatic tumor cell line, Prostate, 24, 119, 10.1002/pros.2990240304 Martinez, 2000, Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial, Int J Radiat Oncol Biol Phys, 47, 343, 10.1016/S0360-3016(00)00436-3 Mate, 1998, High dose-rate afterloading 192-iridium prostate brachytherapy: Feasibility report, Int J Radiat Oncol Biol Phys, 41, 525, 10.1016/S0360-3016(98)00097-2 McMenamin, 1999, Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage, Cancer Res, 59, 4291 Partin, 1993, The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer, J Urol, 150, 110, 10.1016/S0022-5347(17)35410-1 Pesche, 1998, PTEN/MMAC1/TEP1 involvement in primary prostate cancers, Oncogene, 16, 2879, 10.1038/sj.onc.1202081 Pilepich, 1995, Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group, Urology, 45, 616, 10.1016/S0090-4295(99)80053-3 Pilepich MV, Winter K, Roach M, et al: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Phoenix, AZ, 40th Annual ASTRO Meeting, 1998, pp 177 Pollack, 1997, External beam radiotherapy dose response of prostate cancer, Int J Radiat Oncol Biol Phys, 39, 1011, 10.1016/S0360-3016(97)00508-7 Pollack, 2000, Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer, J Clin Oncol, 18, 3904, 10.1200/JCO.2000.18.23.3904 Porter, 1993, Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer, Int J Radiat Oncol Biol Phys, 25, 805, 10.1016/0360-3016(93)90309-J Poulter, 1992, A report of RTOG 8206: A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases, Int J Radiat Oncol Biol Phys, 23, 207, 10.1016/0360-3016(92)90563-W Roach, 1996, Radiotherapy for high grade clinically localized adenocarcinoma of the prostate, J Urol, 156, 1719, 10.1016/S0022-5347(01)65490-9 Russell, 1994, Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: Results of a randomized prospective trial, Int J Radiat Oncol Biol Phys, 28, 47, 10.1016/0360-3016(94)90140-6 Salazar, 1986, Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report, Cancer, 58, 29, 10.1002/1097-0142(19860701)58:1<29::AID-CNCR2820580107>3.0.CO;2-2 Scherr, 1999, BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy, J Urol, 162, 12, 10.1097/00005392-199907000-00003 Schultheiss, 1995, Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate, Int J Radiat Oncol Biol Phys, 32, 643, 10.1016/0360-3016(95)00149-S Seaward, 1998, Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 42, 1055, 10.1016/S0360-3016(98)00282-X Seaward, 1998, Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation, Cancer J Sci Am, 4, 370 Serafini, 1998, Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial, J Clin Oncol, 16, 1574, 10.1200/JCO.1998.16.4.1574 Sharifi, 1996, Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer, Clin Ther, 18, 647, 10.1016/S0149-2918(96)80215-3 Shipley, 1995, Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone, Int J Radiat Oncol Biol Phys, 32, 3, 10.1016/0360-3016(95)00063-5 Shipley, 1999, Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis, JAMA, 281, 1598, 10.1001/jama.281.17.1598 Smit, 1990, Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose, Int J Radiat Oncol Biol Phys, 18, 23, 10.1016/0360-3016(90)90262-I Sneller, 1992, Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study, J Urol, 147, 962, 10.1016/S0022-5347(17)37434-7 Tong, 1982, The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group, Cancer, 50, 893, 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y Welsh, 2000, Samarium-153 lexidronam combined with external beam radiation for the treatment of bone metastases, Case Studies in Oncology, 2, 1 Wick, 1999, PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis, Oncogene, 18, 3936, 10.1038/sj.onc.1202774 Yonemoto, 1997, Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study, Int J Radiat Oncol Biol Phys, 37, 21, 10.1016/S0360-3016(96)00311-2 Zagars, 1993, Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy, Cancer, 72, 1709, 10.1002/1097-0142(19930901)72:5<1709::AID-CNCR2820720535>3.0.CO;2-O Zelefsky, 1998, Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer, Int J Radiat Oncol Biol Phys, 41, 491, 10.1016/S0360-3016(98)00091-1 Zelefsky, 2000, Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer, Radiother Oncol, 55, 241, 10.1016/S0167-8140(99)00100-0